EPISOD后续:2010-2019年Oddi括约肌功能障碍内镜下括约肌切开术使用趋势
基于美国超300家医院电子健康记录数据,2010-2019年新诊断Oddi括约肌功能障碍(SOD)患者中,胆道和胰腺括约肌切开率分别从34.3%和25%降至24.5%和16.4%(P<.001),而SOD发病率从2.4/10万升至12.8/10万(P<.001)。Oddi括约肌测压每年使用不足20次,2013年EPISOD试验后括约肌切开率突然且持续下降。
要点
- 2013年后新诊断SOD患者的内镜下括约肌切开率突然且持续下降。
- SOD发病率从2.4/10万增至12.8/10万,但括约肌切开率反而降低。
- Oddi括约肌测压使用极少(每年<20次),未常规开展。
核心结论
- 在不常规使用Oddi括约肌测压的广泛实践环境中,2013年起新诊断SOD患者的内镜下括约肌切开率出现突然且持续的下降。
研究设计与样本
- 基于美国超300家医院电子健康记录数据库(Explorys)的回顾性队列研究,纳入2010-2019年每年首次诊断「Oddi括约肌功能障碍」的患者,无法按SNOMED-CT编码区分SOD亚型。
主要发现
- 数据库中共有39,950,800名活跃患者,研究期间有7,750例SOD索引诊断。
- SOD发病率从2010年的2.4/10万升至2019年的12.8/10万(P<.001)。
- 胆道括约肌切开率从34.3%降至24.5%,胰腺括约肌切开率从25%降至16.4%(P<.001)。
- Oddi括约肌测压每年使用不足20次;三环类抗抑郁药、硝苯地平或血管扩张性硝酸酯类的新处方无显著增加。
临床怎么用
- 2013年EPISOD试验结果发表后,临床实践中对Type III SOD的内镜下括约肌切开使用明显减少,提示高质量随机对照试验可推动真实世界实践改变。
局限性
- 使用SNOMED-CT编码无法对SOD进行亚型分类。
- 数据来源于不常规使用Oddi括约肌测压的实践环境,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: For years, the endoscopic management of the disorder formerly known as Type III Sphincter of Oddi Dysfunction (SOD) had been controversial. In 2013, the results of the Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) trial demonstrated that there was no benefit associated with endoscopic sphincterotomy for patients with Type III SOD. We aimed to assess the utilization of endoscopic sphincterotomy for patients with SOD in a large population database from 2010-2019. METHODS: We searched a large electronic health record (EHR)-based dataset incorporating over 300 individual hospitals in the United States (Explorys, IBM Watson health, Armonk, NY). Using Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT) we identified patients with a first-ever diagnosis of "disorder of Sphincter of Oddi" annually from 2010-2019. Subclassification of SOD types was not feasible using SNOMED-CT codes. Stratified by year, we identified the proportion of patients with newly-diagnosed SOD undergoing endoscopic sphincterotomy and those receiving newly-prescribed medical therapy. RESULTS: A total of 39,950,800 individual patients were active in the database with 7,750 index diagnoses of SOD during the study period. The incidence rates of SOD increased from 2.4 to 12.8 per 100,000 persons from 2010-2019 (P < .001). In parallel, there were reductions in the rates of biliary (34.3% to 24.5%) and pancreatic sphincterotomy (25% to 16.4%), respectively (P < .001). Sphincter of Oddi manometry (SOM) was infrequently utilized, <20 times in any given year, throughout the study duration. There were no significant increases in new prescriptions for TCAs, nifedipine, or vasodilatory nitrates. CONCLUSIONS: Among a wide range of practice settings which do not utilize routine SOM, a sudden and sustained decrease in rates of endoscopic sphincterotomy for newly-diagnosed SOD was observed beginning in 2013. These findings highlight the critical importance of high-quality, multi-center, randomized controlled trials in endoscopy to drive evidence-based changes in real-world clinical practice.
引用
- Smith ZL, Shah R, Elmunzer BJ, et al. The Next EPISOD: Trends in Utilization of Endoscopic Sphincterotomy for Sphincter of Oddi Dysfunction from 2010-2019. Clin Gastroenterol Hepatol. 2020. PMID: 33161159. doi:10.1016/j.cgh.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。